Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      DUODOPA (levodopa/carbidopa intestinal gel)

      triple all 2
      triple all 4

      DUODOPA
      (levodopa/carbidopa intestinal gel)

      triple all 2
      triple all 4

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)

      triple all 2
      triple all 4

      PRODUODOPA
      (foslevodopa/foscarbidopa solution for infusion)

      triple all 2
      triple all 4
      tftt banner v2
      mobile varient

      A look at Complex/Advanced Parkinson's disease

      DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.2

      Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1,2

      Some patients may not be suitable for DUODOPA or PRODUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

      Sub-optimally controlled symptoms of PD can have a negative impact on a patient’s life3-7

      Patients with PD who experience ‘OFF’ time may have difficulty performing everyday activities and communicating effectively5,8-10

      In an online US survey of 2,110 patients with PD, that assessed their lived experience of ‘OFF’ periods:

      Nearly a quarter of their waking hours were spent in ‘OFF’ state (mean disease duration 6.1 years), which comprised both motor and non-motor symptoms.8

      Patients with PD reported a wide range of motor symptoms during their ‘OFF’ times, with some describing these symptoms as ‘constant tremors’, being ‘frozen in place’ and ‘moving in slow motion’.8

      View Study Information

      Findings from 3 studies whose aims all included exploring the impact of ‘OFF’ periods on PD patients (An online survey of 305 patients exploring the impact of ‘OFF’ time on health related quality of life and daily functioning in people with PD, a scoping review that included 23 studies that evaluated the impact or experience of ‘OFF’ periods in PD patients, and an epidemiological survey of a multicentre, observational cross-sectional study of 617 patients assessing the frequency of wearing ‘OFF’ in patients with PD and its impact on quality of life).

      ‘OFF’ times made it impossible for them to leave the house on their own and affected their ability to communicate effectively.5,9,10

      View Study Information

      The patient perspective: Effect on functioning and ability to undertake usual activities

      What is most bothersome about ‘OFF’ time? Results from an online survey of patients with Complex/Advanced PD experiencing motor fluctuations/wearing off with levodopa5

      Activities rated as most bothersome due to being most limited during ‘OFF’ time (N=305)5

      Adapted from Kerr C et al, 2016.

       

      Approximately 75% of care is provided by a
      spouse/partner for 10 years or more12

       

      Discover why earlier patient assessment for non-oral therapies is important

      Learn more

      Stay connected

      Keep up to date with future resources, support, and guidance to help you manage your patients with PD by filling out your details below and joining the mailing list.

      Please only fill out your details if you are a UK registered healthcare professional.

      Please enter First name
      Please enter Last name
      E-mail address is not valid
      Please enter Hospital name
      I consent to receive AbbVie Ltd communications


      Please refer to the AbbVie privacy notice for more information on how AbbVie processes your personal data and your data privacy rights.

      *Denotes mandatory field

      Incorrect. Please try again.

      1. DUODOPA (levodopa/carbidopa intestinal gel) SmPC.

      2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) SmPC.

      3. Pahwa R, et al. Parkinsonism Relat Disord. 2019; 60: 118–25.

      4. Odin P, et al. Parkinsonism Relat Disord. 2015; 21: 1133–44.

      5. Kerr C, et al. Qual Life Res. 2016; 25(6): 1505–15.

      6. Haahr A, et al. J Adv Nurs. 2011; 67(2): 408–17.

      7. Antonini A, et al. Neurol Ther. 2022; 11(1): 303–18.

      8. Mantri S, et al. J Patient Cent Res Rev. 2021; 8(3): 232–8.

      9. Rastgardani T, et al. Mov Disord Clin Pract. 2018; 5(5): 461–70.

      10. Stocchi F, et al. Parkinsonism Relat Disord. 2014; 20(2): 204–11.

      11. Smolensky L, et al. Sci Data. 2020; 7(1): 67.

      12. Hassan A, et al. Parkinsonism Relat Disord 2012; Suppl 3: S10-14.

      DUODOPA PRESCRIBING INFORMATION
      PRODUODOPA PRESCRIBING INFORMATION

      By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-PRODD-240195. Date of preparation: December 2024

      Mantri S, et al. 20218

      Study type: Online survey.

      Aim: To assess the lived experience of ‘OFF’ periods for people with Parkinson’s disease.

      Patient population: 2,110 people living in the US, who had self-reported Parkinson’s disease (PD), reporting taking 1 or more PD medications, and reported experiencing periods of ‘OFF’ time at the start of the survey (a subset of the Fox Insight* cohort).

      Methods: The survey assessed: (1) what patients called periods where their PD symptoms return when talking to friends and family, (2) description of the ‘OFF’ experience, (3) triggers for ‘OFF’ symptoms, (4) coping strategies for ‘OFF’ time, outside of medication.

      *Fox Insight is an online, longitudinal health study of people with and without PD to provide insight into the lived experience, genetics and variability of PD.11

      Kerr C, et al. 20165

      Study type: Online survey.

      Aim: To explore the impact of ‘OFF’ time on health-related quality of life (HRQoL) and daily functioning in people with Parkinson’s (PwP) relative to ‘ON’ time.

      Patient population: 305 people across the UK, France, Spain and Italy with advanced Parkinson’s experiencing motor fluctuations/wearing-off with levodopa.

      Methods: The survey explored: (1) the impact of ‘OFF’ time on HRQoL, (2) the impact of ‘OFF’ time on functioning and ability to undertake usual activities, and (3) the value of ‘OFF’ time relative to other factorsassociated with Parkinson’s through a stated preference discrete choice experiment (SPDCE).

      Rastgardani T, et al. 20189

      Study type: A scoping review.

      Aim: To research on understanding, impact, and communication regarding ‘OFF’ periods to identify issues warranting further research.

      Methods: The relevant literature was found by searching MEDLINE, EMBASE, Cochrane Library, CINAHL, and PsycINFO from 2006 to January 2018 for “wearing off”, “fluctuations”, “Parkinson”, “impact” and “communication” and refined by the investigators. Overall, 26 studies were included – 23 evaluated the impact or experience of ‘OFF’ periods in patients, three evaluated the impact upon carepartners, two papers addressed understanding of ‘OFF’ periods, one study evaluated communication about ‘OFF’ periods, and three studies evaluated a facilitator of communication about ‘OFF’ periods.

      Patient populations of interest: (1) patients with Parkinson’s disease (PD) experiencing ‘OFF’ periods, (2) carepartners of patients with ‘OFF’ periods, and (3) practising physicians managing patients with ‘OFF’ periods.

      Publication types of interest: (1) survey studies, (2) qualitative or mixed-methods studies, and (3) randomised or pragmatic controlled trials or observational studies that described the impact of interventions to promote and support communication about ‘OFF’ periods.

      Objectives: (1) what is known about the personal experience and impact of ‘OFF’ periods on patients and carepartners beyond global reduction in health-related quality of life, (2) the understanding of ‘OFF’ periods among patients, carepartners, and their physicians, and (3) communication regarding ‘OFF’ symptoms between patients, carepartners, and physicians.

      Stocchi F, et al. 2014 – The DEEP study10

      Study type: An epidemiological survey of a multicentre, observational cross-sectional study.

      Aim: To assess the frequency of Wearing-OZ (WO) in patients with Parkinson’s disease (PD), and its impact on Quality of Life (QoL).

      Patient population: 617 consecutive ambulatory patients with PD, who were on dopaminergic treatment for ≥1 year.

      Methods: In a single visit, WO was diagnosed based on neurologist assessment, as well as using the validated Italian version of a patient self-rated 19-question Wearing-OZ Questionnaire (WOQ-19); WO was defined for scores ≥2. QoL was evaluated by the 8-item Parkinson’s Disease Questionnaire (PDQ-8).

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.